5 Cell and Gene Therapy Decisions to Watch in 2024

From gene-corrected cell therapies to a new CAR-T, the cell and gene therapy space looks to expand its reach into the market.

In 2023, cell and gene therapy saw an unprecedented surge with seven FDA approvals, and this year, an even greater number of these treatments could reach the market. So far in 2024, the regulator has given the green light to three new CGTs, and at least seven additional cell and gene therapy products are expected to receive approval by year’s end, according to a March report from the Alliance for Regenerative Medicine.

Back to news